A detailed history of Harding Loevner LP transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Harding Loevner LP holds 823,627 shares of VRTX stock, worth $395 Million. This represents 2.31% of its overall portfolio holdings.

Number of Shares
823,627
Previous 1,152,625 28.54%
Holding current value
$395 Million
Previous $536 Million 38.13%
% of portfolio
2.31%
Previous 3.14%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$396.64 - $516.74 $130 Million - $170 Million
-328,998 Reduced 28.54%
823,627 $332 Million
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $14.6 Million - $16.1 Million
-31,783 Reduced 2.68%
1,152,625 $536 Million
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $15.2 Million - $18.8 Million
-38,630 Reduced 3.16%
1,184,408 $555 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $40 Million - $43.8 Million
-98,191 Reduced 7.43%
1,223,038 $511 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $8.75 Million - $10.5 Million
-25,522 Reduced 1.9%
1,321,229 $538 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $64.8 Million - $69.4 Million
-191,519 Reduced 12.45%
1,346,751 $468 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $90.7 Million - $101 Million
-288,354 Reduced 15.79%
1,538,270 $541 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $3.94 Million - $4.49 Million
-13,897 Reduced 0.76%
1,826,624 $576 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $57.4 Million - $64.5 Million
200,704 Added 12.24%
1,840,521 $532 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $25.7 Million - $28.7 Million
-93,874 Reduced 5.41%
1,639,817 $475 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $8.36 Million - $10.4 Million
-35,585 Reduced 2.01%
1,733,691 $489 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $24.9 Million - $29.4 Million
-112,595 Reduced 5.98%
1,769,276 $417 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $5.17 Million - $6.53 Million
-29,232 Reduced 1.53%
1,881,871 $413 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $16 Million - $17.9 Million
-87,975 Reduced 4.4%
1,911,103 $347 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $3 Million - $3.54 Million
15,989 Added 0.81%
1,999,078 $403 Million
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $12.4 Million - $14.5 Million
-60,006 Reduced 2.94%
1,983,089 $426 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $8.81 Million - $11.7 Million
42,554 Added 2.13%
2,043,095 $483 Million
Q3 2020

Nov 16, 2020

SELL
$255.65 - $303.1 $5.43 Million - $6.43 Million
-21,226 Reduced 1.05%
2,000,541 $544 Million
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $5.75 Million - $7.54 Million
-25,507 Reduced 1.25%
2,021,767 $587 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $8.87 Million - $11 Million
-44,382 Reduced 2.12%
2,047,274 $487 Million
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $38.6 Million - $51.8 Million
-231,426 Reduced 9.96%
2,091,656 $458 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $263 Million - $296 Million
1,582,711 Added 213.77%
2,323,082 $394 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $1.92 Million - $2.22 Million
-11,673 Reduced 1.55%
740,371 $136 Million
Q1 2019

May 15, 2019

BUY
$163.73 - $194.7 $123 Million - $146 Million
751,975 Added 1089818.88%
752,044 $138 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $10,481 - $13,262
69 New
69 $11,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $123B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Harding Loevner LP Portfolio

Follow Harding Loevner LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harding Loevner LP, based on Form 13F filings with the SEC.

News

Stay updated on Harding Loevner LP with notifications on news.